SCHEMBL4408264

SCHEMBL4408264

Cc1noc2nc(-c3ccc(F)cc3)c(-c3ccnc(N(C)C4CC4)n3)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.40
MAPK14 Q16539 3/20 0.34
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
GRIA1 P42261 1/20 0.33
LMNA P02545 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
IRAK4 Q9NWZ3 2/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
MAPK10 P53779 1/20 0.32
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4412109 0.82 DYRK1A (0.39) DYRK1AMAPK14MAPK13MAPK12MAPK11
SCHEMBL2926186 0.82 DYRK1A (0.39) DYRK1AMAPK14GRIA1
SCHEMBL4407549 0.78 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK11LMNA
SCHEMBL4408259 0.78 MAP4K4 (0.50) DYRK1AMAPK14MAPK13MAPK12MAPK11
SCHEMBL4415345 0.77 DYRK1A (0.39) DYRK1AMAPK14MAPK13MAPK12MAPK11
SCHEMBL4409899 0.76 ALDH1A1 (0.40) MAPK14MAPK13MAPK12MAPK11LMNA
SCHEMBL2927863 0.75 DYRK1A (0.41) DYRK1AMAPK14MAPK13MAPK12MAPK11
SCHEMBL4408485 0.71 MAPK13 (0.55) DYRK1AMAPK14MAPK13MAPK12MAPK11
SCHEMBL4408488 0.71 MAPK13 (0.55) DYRK1AMAPK14MAPK13MAPK12MAPK11
SCHEMBL4412384 0.71 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US claimed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US claimed
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US disclosed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 DYRK1A 1722/4885MAPK14 36/4885MAPK13 39/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 DYRK1A 1722/4885MAPK14 36/4885MAPK13 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.